Compare AUUD & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUUD | PPCB |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | Australia |
| Employees | 5 | 2 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.3M |
| IPO Year | N/A | N/A |
| Metric | AUUD | PPCB |
|---|---|---|
| Price | $1.85 | $0.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 1.3M |
| Earning Date | 05-11-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.07 |
| 52 Week High | $10.10 | $10.69 |
| Indicator | AUUD | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 28.06 |
| Support Level | $0.74 | N/A |
| Resistance Level | $1.95 | $0.13 |
| Average True Range (ATR) | 0.20 | 0.01 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 64.29 | 3.90 |
Auddia Inc is a United States-based company. It operates through its proprietary AI platform for audio and is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. The group Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Its flagship audio superapp, called faidr, delivers multiple industry firsts, including: Ad-free listening on any AM/FM radio station, Content skipping across any AM/FM station, One-touch skipping of entire podcast ad breaks, and Integrated artist discovery experiences.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.